Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India by Mandal, Swati et al.
Assessing aquaglyceroporin gene status and expression profile
in antimony-susceptible and -resistant clinical isolates
of Leishmania donovani from India
Swati Mandal1, Mahendra Maharjan1, Sarman Singh2, Mitali Chatterjee3 and Rentala Madhubala1*
1School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India; 2Division of Clinical Microbiology, All India
Institute of Medical Sciences, New Delhi, India; 3Institute of Post Graduate Medical Education and Research, Kolkata, India
*Corresponding author. Tel/Fax: þ91-11-26742630; E-mail: madhubala@mail.jnu.ac.in
Received 8 September 2009; returned 9 October 2009; revised 25 November 2009; accepted 26 November 2009
Objectives: Clinical resistance to pentavalent antimonials results from an interplay between uptake, efflux and
sequestration in Leishmania. Aquaglyceroporins (AQPs) have been shown to facilitate uptake of trivalent met-
alloids. Down-regulation of AQP1 in Leishmania results in resistance to trivalent antimony, whereas overexpres-
sion of AQP1 in drug-resistant parasites can reverse the resistance. The present work investigates the role of
AQP1 in monitoring antimonial resistance in Indian leishmaniasis.
Methods and results: Susceptibility to trivalent antimony as determined in vitro with intracellular amastigotes
from both visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL) patients correlated well
with the clinical response. Higher accumulation of trivalent antimony (SbIII) was observed in all susceptible iso-
lates compared with resistant isolates. Reduced accumulation of SbIII correlated, with a few exceptions, with
down-regulation of AQP1 RNA as determined by real-time PCR. Cloning and sequencing of the AQP1 gene from
both VL and PKDL isolates showed sequence variation in four of the clinical isolates. None of the isolates had an
alteration of Glu152 and Arg230, which have been previously shown to affect metalloid transport. Transfection
of the AQP1 gene in a sodium antimony gluconate-resistant field isolate conferred susceptibility to the resistant
isolate.
Conclusions: Our studies indicate genetic variation in VL and PKDL isolates. Down-regulation of AQP1 correlates
well with clinical drug resistance in a majority of Indian VL and PKDL isolates. AQP1 gene expression at both the
genetic and transcriptional level showed positive correlation with SbIII accumulation, with some exceptions.
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Introduction
Visceral leishmaniasis (VL) is a parasitic disease caused by the
protozoan parasite Leishmania donovani. VL is thought to be
anthroponotic in India, and post-kala-azar dermal leishmaniasis
(PKDL) patients are considered to serve as a source for new out-
breaks.1 PKDL is a cutaneous manifestation of VL. In India and
Sudan the disease develops months to years after the patient
has recovered from VL.2 Current chemotherapeutic agents are
ineffective because of their high toxicity and emergence of
drug resistance. The pentavalent antimonial, sodium antimony
gluconate (SAG or SbV), is the age-old conventional therapy for
VL.3 However, increasing resistance to SAG has emerged as a
major barrier in the treatment of VL.
Resistance to SAG in field isolates is less well defined. Recent
reports show that determination of susceptibility using in vitro
assays correlates well with the clinical response.4 – 6 Our previous
studies showed that mechanisms of resistance to antimony
reported in laboratory strains are also operational in field iso-
lates.7 Variability in the mechanism of resistance and a varying
degree of resistance were encountered in field isolates.7 Develop-
ment of drug resistance has been a hindrance in chemotherapy
of leishmaniasis and is of considerable importance to identify
biomarkers responsible for resistance to antimonials for VL. A
number of candidate genes associated with resistance to anti-
monials have been described in both SAG-resistant laboratory
mutants and clinical isolates of L. donovani.8 – 10
Aquaglyceroporins (AQPs) are members of the aquaporin
superfamily. They are membrane channels which permit trans-
port of small neutral solutes such as glycerol or urea. In Leishma-
nia species, AQP1 has been shown to facilitate trivalent antimony
(SbIII) transport.11 Overexpression of AQP in Leishmania major
(LmAQP1) produces hypersusceptibility to SbIII, whereas gene
deletion renders the parasite resistant.11,12 This has provided
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a major insight into the uptake mechanism of drugs in
L. major.11,13 Prediction of the topology of L. major AQP1
showed that LmAQP1 consists of six membrane-spanning
helices containing the canonical Asn-Pro-Ala (NPA) motifs.14
These helices are connected by five loops referred to as A–E.14
Glutamate (Glu152) present in the C-loop of LmAQP1 is reported
to be critical for metalloid permeability. A single mutation from
Glu152 to alanine selectively abrogates metalloid permeability.14
In the present study we examined the role of AQP1 in monitor-
ing antimonial resistance in Indian leishmaniasis. Susceptibility to
SAG as determined in vitro with intracellular amastigotes from
both VL and PKDL patients correlated well with the clinical
response. A positive correlation between AQP1 gene expression
and SbIII accumulation in both VL and PKDL field isolates was
observed. Cloning and sequencing of the AQP1 gene from both
VL and PKDL isolates was also performed to check the role of
Glu152 and Arg230 in antimony resistance. Transfection of the
AQP1 gene in an SAG-resistant field isolate conferred susceptibility
to the resistant isolate. Our results demonstrate that down-
regulation of AQP1 correlates well with the antimony drug resist-
ance in a majority of Indian VL and PKDL isolates.
Materials and methods
Study population
Patients clinically diagnosed with VL (fever and hepatosplenomegaly)
were recruited from the outpatient department of Medicine, Institute
of Postgraduate Medical Education and Research, Kolkata, West Bengal.
They gave a history of either residence in or travel to Bihar, India. The
diagnosis of VL was performed by rK39 dip test and, if found positive,
was confirmed by bone marrow aspiration and microscopic examination
of Giemsa-stained smears that demonstrated the presence of
L. donovani bodies. The bone marrow/splenic aspirates were collected
aseptically and transferred to agar slants containing 1 mL of modified
M199 medium (Sigma, USA) supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Gibco/BRL, Life Technologies, Scotland, UK) and
0.13 mg/mL penicillin and streptomycin (medium A). Parasite transform-
ation was checked and, when a sufficient number of parasites was
obtained (.5106), they were then adapted to medium A.
Patients who were clinically diagnosed with PKDL were recruited from
the outpatient unit of the Department of Dermatology, School of Tropical
Medicine, West Bengal. The diagnosis was based on clinical features and
a past history of VL, which was corroborated by rK39 strip test and the
presence of L. donovani bodies in dermal lesions. The punch biopsy
material, collected aseptically, was cut into small pieces and placed in
a 25 mm2 tissue culture flask containing Schneider’s medium (Sigma,
USA) supplemented with 10% FBS, 0.13 mg/mL penicillin and streptomy-
cin. After successful transformation, when the cell number exceeded
5106, they were gradually adapted to medium A.
Once transformed, both VL and PKDL isolates were cloned on semi-
solid M199 medium containing 1% Bacto agar (Difco) and 10%
heat-inactivated FBS. Colonies were picked after 6–7 days and trans-
ferred to medium A.
Ethical approval was obtained from the institutional review boards of the
Institute of Post Graduate Medical Education and Research and School of
Tropical Medicine, Kolkata, India, and informed consent was obtained.
Parasite and culture conditions
Promastigotes of L. donovani clones AG83 (MHOM/IN/80/AG83), 2001,
MC4, MC7, MC8 and MC9 were isolated from patients with VL, and
strains RK1, MS2, NR3A, RMP8 (HM/IN/RMP8), RMP19 (HM/IN/RMP19),
RMP142 (HM/IN/RMP142), RMP155 (HM/IN/RMP155) and RMP240 (HM/
IN/RMP240) were isolated from patients with PKDL. Both VL and PKDL
strains were from the antimony-resistant zone of Bihar, India. PKDL iso-
lates RMP8 (HM/IN/RMP8), RMP19 (HM/IN/RMP19), RMP142 (HM/IN/
RMP142), RMP155 (HM/IN/RMP155) and RMP240 (HM/IN/RMP240) were
a gift from the Division of Clinical Microbiology, All India Institute of
Medical Sciences, New Delhi.15 SAG-susceptible strains AG83 and 2001
were used as reference strains and have been characterized previously.7
Promastigotes were routinely cultured at 228C in modified M199
medium (Sigma, USA) supplemented with 10% heat-inactivated FBS
and 0.13 mg/mL penicillin and streptomycin. There was no difference in
the growth rate of these isolates. Clinical isolates obtained from VL and
PKDL patients who responded to SAG chemotherapy were designated
as SAG susceptible (SAG-S), whereas isolates from VL and PKDL patients
who did not respond to SAG were designated as SAG resistant (SAG-R).
Accordingly, SAG-S isolates used in this study included AG83-S, 2001-S,
MC7-S, RK1-S and MS2-S, whereas the nine SAG-R isolates were MC4-R
MC8-R, MC9-R, NR3A-R, RMP8-R, RMP19-R, RMP142-R, RMP155-R and
RMP240-R. These clinical isolates were maintained in the absence of
drug pressure in vitro. The isolates were routinely passaged through
BALB/c mice to retain their virulence. This study was approved by the
Institutional level ethics committee.
DNA construct and transfection
The linearized b-lactamase expression vector (pIR1SAT-bLA) containing a
b-lactamase-encoding gene used in the present study was a kind gift of
Dr Frederick S. Buckner (Washington University, Seattle, WA, USA). When
linearized, this vector integrates into the Leishmania genome by replacing
one copy of the small subunit rRNA gene. The construct was linearized by
SwaI restriction digestion (MBI, Fermentas), and 10 mg of the linearized
construct having the b-lactamase gene was transfected into L. donovani
log-phase promastigotes (4107) by electroporation. Briefly, electropora-
tion was done in 2 mm gap cuvettes at 450 V and 500 mF (Bio-Rad) as
reported previously.16 The transfectants were selected for resistance to
50 mg/mL nourseothricin (Sigma, USA).16,17
Chemosensitivity profiles of SAG-S and SAG-R strains
in an amastigote macrophage model using a
b-lactamase assay
Stationary-phase Leishmania promastigotes expressing the b-lactamase
gene were used to infect J774A.1 macrophages. The macrophage cell
line J774A.1 (ATCC) was maintained at 378C in RPMI-1640 medium
(Sigma, USA) containing 10% heat-inactivated FBS. Briefly, the intracellu-
lar amastigotes grown in macrophages were quantified for b-lactamase
activity by removing the medium by gentle pipetting followed by addition
of 50 mL of 50 mM CENTA (Calbiochem, La Jolla, CA, USA) in PBS and 0.1%
Nonidet P-40. The plates were incubated at 378C for 4 h.16,17 Catalysis of
the substrate (CENTA) to its chrome yellow colour product was quantified
at an optical density of 405 nm using a 96-well plate reader (Bio-Rad).17
The IC50 was determined from the graph representing different concen-
trations of the inhibitor plotted against percentage growth.
Determination of in vitro antileishmanial activity
in promastigote cultures
In order to characterize the SAG susceptibility profile of L. donovani pro-
mastigotes, a modified MTT (Sigma, USA) assay was performed as des-
cribed previously.18 Briefly, 25 mL of promastigotes (2.5104 cells/well)
were cultured in a 96-well flat-bottomed plate (Nunc, Roskilde,
Denmark) and incubated with 25 mL of different drug concentrations at
268C. After 72 h, 10 mL of MTT (5 mg/mL) in 1 PBS was added to each
AQP1 of L. donovani and antimony resistance
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well and the plates were incubated at 378C for 3 h. The reaction was
stopped by the addition of 50 mL of 50% isopropanol and 10% SDS.
The plates were again incubated for 30 min at 378C with gentle
shaking. Absorbance was measured at 570 nm in a microplate reader.
The IC50 (50% inhibitory concentration) was determined from the
graph representing different concentrations of the inhibitor plotted
against percentage cell growth.
Drug uptake assay
Uptake studies were performed as described previously.13 Briefly, log-
phase Leishmania promastigotes of SAG-S isolates (AG83-S, 2001-S,
MC7-S, RK1-S and MS2-S) and SAG-R isolates (MC4-R, MC8-R, NR3A-R,
RMP8-R, RMP19-R, RMP142-R, RMP155-R and RMP240-R) were washed
twice with PBS (pH 7.4) and were resuspended in PBS containing
10 mM glucose at a density of 5107 cells/mL. Cells were then incubated
at 278C with 100 mM SbIII for 30 min and 500 mL aliquots were collected
at 0 and 30 min. Cells were pelleted down and washed twice with an
equal volume of ice-cold PBS and centrifuged at 17000 g for 1 min at
room temperature. The pellet was dried and treated with 0.05% of
70% nitric acid for 2 h at 708C and then diluted with 3 mL of HPLC-grade
water. Antimony levels were analysed by inductively coupled plasma
mass spectroscopy (ICP-MS) as reported previously.13,19 Each uptake
assay was repeated twice with triplicates in each set.
Nucleic acid isolation, PFGE and hybridization analysis
Genomic DNA was isolated from 2109 cells from 10–15 mL of a
mid-log-phase promastigote culture of all field isolates by a standard
procedure.20 Genomic DNA (5 mg) was digested with the enzyme SalI
and subjected to electrophoresis. The fragments were transferred to
HybondTM-Nþ membrane (Amersham Pharmacia Biotech) and subjected
to Southern blot analysis.
Chromosomes of the clinical isolates were separated by PFGE in which
low melting agarose blocks, containing embedded cells (108/mL log-
phase promastigotes), were electrophoresed in a contour-clamped
homogeneous electric field apparatus (CHEF DRIII, Bio-Rad) in 0.5 Tris
borate/EDTA, with buffer circulation at a constant temperature of 148C.
The gel running conditions were as follows: voltage gradient of 6 V/cm;
initial switch time of 60 s; final switch time of 120 s; and run time of
24 h. Saccharomyces cerevisiae chromosomes were used as size markers.
Promastigotes (2108) were used for isolation of total RNA using TRI
reagentTM (Sigma, USA). Total RNA (15 mg) was fractionated by denatur-
ing agarose gel electrophoresis and transferred onto a nylon membrane
for northern blot analysis. The blots obtained above were pre-hybridized
at 658C for 4 h in a buffer containing 0.5 M sodium phosphate/7% SDS/
1 mM EDTA (pH 8.0) and 100 mg/mL sheared denatured salmon sperm
DNA. Hybridization was done with a denatured a-[32P]dCTP-labelled
DNA probe at 106 cpm/mL, which was labelled by random priming
(NEB Blotw Kit, New England Biolabs, Inc.). Labelling was performed
according to the manufacturer’s protocol. The DNA probe used in the
present study was a 945 bp AQP1 probe (accession number,
EF600686). Membranes were washed, air dried and exposed to an
imaging plate. The images were developed by PhosphorImager (Fuji
film FLA-5000, Japan) using Image Quant software.
Molecular genotyping by PCR-restriction fragment length
polymorphism (RFLP) of the internal transcribed spacer
(ITS) region of L. donovani clinical isolates
The entire ITS in the ribosomal operon was amplified using the primers:
LITSR, 50-CTGGATCATTTTCCGATG-30; and LITSV, 50-ACACTCAGGTCTGTA
AAC-30.21 A 10 mL aliquot of the amplified ITS region was digested with
HaeIII for 2 h at 378C using the conditions recommended by the
manufacturer. Restriction fragments were separated on a 2% agarose
gel for 2–4 h in 1 Tris borate/EDTA (90 mM Tris borate/0.2 mM EDTA)
buffer and visualized under UV light after staining with ethidium bromide.
cDNA synthesis and real-time RT–PCR
Total RNA was isolated from 108 Leishmania cells in the mid-log phase of
growth using the RNeasy Plus Mini Kit (Qiagen) as described by the manu-
facturer. The RNAs were treated with RQ1 RNase-free DNase (Promega,
Madison, WI, USA) to avoid any genomic DNA contamination. The quality
and quantity of the RNA were determined using the RNA 6000 Nano Lab
Chip Kit on a Bio-analyzer 2100 (Agilent Technologies). The sequences of
the primers for AQP1 were: forward, 50-CTGTGTCTTTGGTGCCTTTCC; and
reverse, 50-GCCTTTTGGGCGTCGTC.22 The sequences of the primers for
the GAPDH (glyceraldehyde phosphate dehydrogenase) control were:
forward, 50-GAAGTACACGGTGGAGGCTG; and reverse, 50-CGCTGATCACG
ACCTTCTTC.7 Complementary DNAs from promastigotes were synthesized
from 500 ng of total RNA using the AccuSuperscript High Fidelity RT-PCR
Kit (Stratagene, La Jolla, CA, USA) and oligo(dT)18 primers following the
manufacturer’s instructions. Real-time PCR was performed in triplicate
in 25 mL volumes using the QuantiFast SYBR Green PCR Master Mix
(Qiagen) in an Applied Biosystem 7500. Reactions were run using the fol-
lowing thermal profile: initial denaturation at 958C for 5 min followed by
40 cycles with denaturation at 958C for 30 s, annealing at 628C for 20 s
and extension at 728C for 20 s. The PCR was followed by a melt curve
analysis to ascertain that the expected products were amplified. The rela-
tive amount of PCR products generated from each primer set was deter-
mined based on the threshold cycle (Ct) value and amplification
efficiencies, and was normalized by dividing the values by the relative
amount of the GAPDH gene used as a control.
Cloning and sequencing of the AQP1 gene from
antimony-susceptible and antimony-resistant
L. donovani isolates
The AQP1 gene from the VL and PKDL clinical isolates was PCR amplified
using specific oligonucleotides. DNA fragments of 945 bp were amplified
from the genomic DNA of 2001-S, AG83-S, MC7-S, MC4-R, MC8-R, MC9-R,
RK1-S, MS2-S, NR3A-R and RMP142-R using a sense primer with a flanking
XbaI site, 50-GCTCTAGAATGAACTCTCCTACAAGCACA-30, and an antisense
primer with a flanking HindIII site, 50-CCCAAGCTTCTAGAAGTTGGGTG
GAATGA-30.23 PCR was performed in a 50 mL reaction volume containing
100 ng of genomic DNA, 25 pmol of each of the gene-specific forward
and reverse primers, 200 mM of each dNTP, 2 mM MgCl2 and 5 U of Taq
DNA polymerase (MBI Fermentas). The conditions of the PCR were as
follows: 948C for 10 min, 948C for 45 s, 608C for 30 s and 728C for 45 s
for a total of 30 cycles. Final extension was carried out for 10 min at
728C. A single-band 945 bp PCR product was obtained and subcloned
into pTZ57R/T (InsTAcloneTM PCR Cloning Kit, MBI Fermentas) and sub-
jected to automated sequencing. Multiple alignment of amino acid
sequences was performed using the CLUSTAL W program. The trans-
membrane domain of the sequences was identified using HMMTOP
protein topology prediction online software (www.enzim.hu/hmmtop).
Transfection and overexpression of the AQP1 gene
The AQP1 gene from the susceptible AG83-S L. donovani strain was PCR
amplified. The amplified DNA fragment was cloned into the XbaI–
HindIII site of the pspaneoa Leishmania shuttle vector (kindly provided
by Dr Marc Ouellette, Quebec, Canada) to create a pspaneoa-AQP1
gene construct containing the neomycin phosphotransferase gene
(G418) antibiotic marker. The construct (20 mg) was transfected into
the promastigotes of the susceptible AG83-S isolate and resistant
MC4-R L. donovani promastigotes by electroporation using the
Mandal et al.
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parameters 450 V and 500 mF (Bio-Rad). Transfectants were selected for
resistance to G418 (40 mg/mL). Transfectants with the pspaneoa vector
alone were used as a control. Drug uptake and susceptibility assays
were performed as described above.
Statistical analysis
Data were analysed using the Student’s t-test. The data are presented as
means+SD. The results are representative of three independent experi-
ments. A P value of ,0.05 was considered to be statistically significant.
Results
Susceptibility and characterization of SAG-S and SAG-R
strains
A total of 14 field isolates were collected from patients residing
in the antimony-resistant zone of Bihar, India. The chemosensi-
tivity profiles of the SAG-S and the SAG-R strains to SbIII were
tested in intracellular amastigotes by a b-lactamase assay as
described in the Materials and methods section. SAG-S isolates
AG83-S, 2001-S, MC7-S, RK1-S and MS2-S from SAG-responsive
patients had IC50 values of 6.2+1.8, 0.9+0.12, 8+3.3,
0.01+0.02 and 4.75+0.12 mM, respectively, whereas the
SAG-R isolates MC4-R, MC8-R, MC9-R, NR3A-R, RMP8-R,
RMP19-R, RMP142-R, RMP155-R and RMP240-R from
SAG-unresponsive patients had IC50 values that were 2- to
.10-fold higher than that of the susceptible isolate AG83-S
(Table 1).
Molecular karyotyping of all L. donovani clinical isolates was
carried out using a contour-clamped homogeneous electric
field apparatus (Figure 1a). The molecular karyotype of PKDL iso-
lates when compared with that of the two VL reference strains,
AG83-S and 2001-S, did not show any difference in the chromo-
some number and size. However, the VL isolates MC7-S, MC4-R,
MC8-R and MC9-R showed a slightly different pattern of
chromosome size and number when compared with the other
VL and PKDL isolates.
RFLP of the amplified ITS has been used successfully as a geno-
typing marker in molecular epidemiology.21 HaeIII restriction
digestion of the entire ITS region was performed to further
confirm the genetic variation in the isolates (Figure 1b and c).
Comparison of the HaeIII restriction digestion pattern of the
amplified ITS region indicated polymorphism among clinical
L. donovani isolates (Figure 1c). With the exception of NR3A-R,
all PKDL isolates had the same banding pattern as that of the
two VL reference strains, AG83-S and 2001-S. On the other
hand, VL isolates MC7-S, MC4-R, MC8-R and MC9-R had three
different polymorphic patterns. Strains MC7-R and MC8-R had a
similar banding pattern.
Accumulation of SbIII in L. donovani clinical isolates
ICP-MS was used to show SbIII accumulation inside the cells at
the 30 min timepoint.13,19 Promastigotes were incubated with
100 mM SbIII for 30 min at 278C as detailed in the Materials
and methods section. Antimony-resistant Leishmania isolates
(SAG-R) had reduced accumulation of SbIII compared with the
SAG-S isolates. In comparison with AG83-S, SAG-R field isolates
MC4-R, MC8-R, MC9-R, NR3A-R, RMP8-R, RMP19-R, RMP142-R,
RMP155-R and RMP240-R accumulated 4.1-, 3.9-, 2.5-,
2.0-, 6.3-, 6.7-, 6.3-, 5.7- and 5.6-fold less SbIII,
respectively (Figure 2).
Gene copy number and expression profiling of the AQP1
gene in SAG-S and SAG-R field isolates
Southern blot analysis showed variation in the gene copy number
of the AQP1 gene in both VL and PKDL isolates. The restriction
enzyme SalI, which digests outside the gene producing a
10.8 kb restriction fragment (expected size), was used to check
the copy number of the gene. A single hybridizing fragment of
Table 1. Susceptibility of SAG-S and SAG-R field isolates to SbIII in intracellular amastigotes
Strain no. Strain ID Geographical location Disease Mean IC50+SD (mM)
1 AG83-S Bihar VL 6.2+1.8
2 2001-S Bihar VL 0.9+0.12
3 MC7-S Siwan, Bihar VL 8+3.3
4 MC4-R Samastipur, Bihar VL 32+5.2 (5.16)*
5 MC8-R Chapra, Bihar VL 26+4.6 (4.2)*
6 MC9-R Samastipur, Bihar VL 18+2.1 (3.0)*
7 RK1-S Bihar PKDL 0.01+0.02
8 MS2-S Bihar PKDL 4.75+0.12
9 NR3A-R Bihar PKDL 52+4.9 (8.4)*
10 HM/IN/RMP8 Bihar PKDL 18.5+1.06 (3.0)*
11 HM/IN/RMP19 Bihar PKDL 14+0.35 (2.3)*
12 HM/IN/RMP142 Bihar PKDL .100.00 (.10.0)*
13 HM/IN/RMP155 Bihar PKDL 40+3.5(6.5)*
14 HM/IN/RMP240 Bihar PKDL 30+1.41(5.0)*
All values presented are means+SD of triplicates from three independent experiments. The fold differences with respect
to the AG83-S strain are shown in parentheses.
*Statistically significant at P,0.001 when compared with the corresponding values obtained for AG83-S.
AQP1 of L. donovani and antimony resistance
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10.8 kb was observed in the VL isolates MC7-S, MC4-R, MC8-R,
MC9-R, 2001-S and AG83-S. PKDL isolates RMP8-R, RMP19-R,
RMP142-R, RMP155-R, RMP240-R and MS2-S also showed a
single hybridizing fragment of 7 kb, indicating that AQP1 exists
as a single copy gene in these strains (Figure 3a). However,
RK1-S had 10.8 and 7 kb bands representing two copies of
AQP1. Interestingly, NR3A-R, a PKDL isolate that was 8.4-fold
resistant to SbIII, showed amplification of the AQP1 gene.
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Figure 1. (a) PFGE of SAG-S and SAG-R VL and PKDL isolates of L. donovani chromosomes. Agarose blocks containing chromosomal DNAs of
promatigotes were prepared and subjected to PFGE for 24 h at 148C as reported in the Materials and methods section. (b) Schematic position of
the internal transcribed spacer (ITS) in the ribosomal operon and position of the primers used to amplify the ITS sequence. Sequences of the
primers LITSR and LITSV are given in the Materials and methods section. SSU, small subunit; LSU, large subunit. (c) RFLP analysis of the amplified
ITS from different clinical L. donovani isolates. Digestion with HaeIII of amplified ITS regions of different VL and PKDL isolates is shown. Fragments
were separated on a 2% agarose gel for 2–4 h to document differences in RFLP patterns. A 100 bp ladder was used as a molecular size marker.
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Comparison of AQP1 gene expression in SAG-S versus SAG-R
field isolates was carried out to verify whether there was any cor-
relation between AQP1 gene expression and the SAG sus-
ceptibility profile of the clinical isolates. Total RNA from
promastigotes of the clinical isolates was isolated and comp-
lementary DNAs were synthesized. Real-time PCR using Quanti-
Fast SYBR Green PCR Master Mix (Qiagen) with AQP1
(gene-specific) and GAPDH (internal control) primers was per-
formed. Down-regulation of AQP1 expression was observed in
the resistant clinical isolates. AQP1 expression in the resistant
strains MC4-R, MC9-R RMP8-R, RMP19-R, RMP142-R, RMP155-R
and RMP240-R was 5.2-, 4.2-, 2.8-, 3.1-, 2.7-, 2.2- and 4.5-fold
less, respectively, compared with the expression in the suscep-
tible isolate AG83-S (Figure 3b). In the present study, although
down-regulation of AQP1 was observed in the majority of the
SAG-R isolates, there were two exceptions. Two SAG-resistant
strains, NR3A-R and MC8-R, showed up-regulation of AQP1
gene expression. NR3A-R and MC8-R were 8.4- and 4.2-fold
resistant to SbIII, respectively, as compared with the susceptible
isolate AG83-S. AQP1 gene expression levels of susceptible clini-
cal isolates 2001-S, MC7-S, RK1-S and MS2-S were similar to that
of the SAG-S isolate, AG83-S.
Comparison of sequence analysis of the AQP1 gene
of SAG-S and SAG-R field isolates
Down-regulation of LmAQP1 is reported to be linked to antimony
resistance.13 Introduction of point mutations in transporter
proteins is yet another mechanism of drug resistance in
Leishmania.24,25 Recently, a point mutation in the extracellular
loop of the LmAQP1 channel, at Glu152 (corresponding to
Glu185 in the full-length sequence), was shown to confer SbIII
resistance in L. major laboratory mutants.14 The full-length
coding sequence (945 bp) of the L. donovani AQP1 gene was
cloned and sequenced from six VL and five PKDL isolates. The
transmembrane topology of the proteins was predicted using
an online transmembrane topology prediction server (HMMTOP;
www.enzim.hu/hmmtop). Six transmembrane domains (TM1–
TM6) and five helical loops (A–E) connecting transmembrane
domains were identified in the L. donovani sequence (Figure 4).
The predicted protein sequence of the susceptible strains
AG83-S, 2001-S and RK1-S was similar to that of the
SAG-resistant strains MC9-R and NR3A-R (Figure 4). The hourglass
model of aquaporin reported previously26,27 has been used to
show mutations observed in the AQP1 protein of different
L. donovani field isolates (Figure 5a). The model shows the pres-
ence of six transmembrane domains (1–6) connected by five
helical loops (A–E). Loops B and E contain conserved Asn-Pro-Ala
(NPA) motifs and form short a-helices that fold back into the
membrane from the opposite side forming a channel for glycerol
transport. Interestingly, AQP1 sequence polymorphism was
observed in MC7-S, MS2-S, MC4-R and MC8-R, with differences
either in the transmembrane domains or in the helical loops
(Figures 4 and 5), but none of the differences was uniform. Con-
served signatures of the AQP1 protein were deduced from the
multiple sequence alignments shown in Figure 4. Specific vari-
ation in the sequences of the isolates is shown in Figure 5(b).
Point mutation at Glu185 and Arg263 residues (corresponding
to Glu152 and Arg230)14 could not be detected in any of the
resistant field isolates, indicating that the SAG resistance pheno-
type, at least in Indian L. donovani VL and PKDL field isolates,
does not result from the point mutation of Glu185 and Arg263
residues of the sequence encoded by the AQP1 gene.
Overexpression of AQP1 in an antimony-resistant field
isolate conferred increased expression and susceptibility
to antimony, and facilitated SbIII uptake
To determine whether overexpression of AQP1 conferred suscepti-
bility to resistant isolates, we transfected the AQP1 construct into
the promastigotes of both the antimony-susceptible isolate
AG83-S and the antimony-resistant isolate MC4-R. Increased
expression of AQP1 in transfected AG83-S and MC4-R strains was
confirmed by comparison of northern blot analysis of vector-
transfected controls and AQP1-transfected lines (Figure 6a). The
role of AQP1 in the uptake of SbIII was investigated. LdAQP1-
transfected strains AG83-S and MC4-R showed rapid uptake of
SbIII compared with vector-control transfectants (Figure 6a).
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Figure 2. Accumulation of SbIII in VL and PKDL L. donovani field isolates
as measured by ICP-MS. Promastigotes were incubated with 100 mM
SbIII for 30 min at 278C as described in the Materials and methods
section. Data are shown as means+SD of two replicate experiments
with triplicates in each set. *P,0.01 and **P,0.001 when compared
with AG83-S isolate values.
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Figure 3. (a) Southern blot analysis of the AQP1 gene in the SAG-S and the SAG-R L. donovani VL and PKDL field isolates. Total genomic DNA was
isolated and digested with SalI. The digested DNA was electrophoresed, blotted and hybridized with a full-length AQP1-specific probe of 945 bp.
The sizes of the hybridizing bands were determined using HindIII-digested l DNA. The blot was re-hybridized with an a-tubulin probe to monitor
the amount of digested DNA layered on the gel. (b) Real-time RT–PCR expression analysis of AQP1 in L. donovani clinical isolates. AQP1 RNA
expression ratios in the SAG-resistant isolates relative to the SAG-susceptible isolate AG83. Results are the means of three independent
experiments performed using three different RNA preparations.
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AG83-S          MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
2001-S          MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
MC7-S           MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
MC4-R           MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
MC8-R           MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
MC9-R           MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
RK1-S           MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
MS2-S           MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
NR3A-R          MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
RMP142-R        MNSPTSTPPACYDAEVQLYMDKEDPEGVPIQNQMHEEEQGQLEGKRNFTSQNRWPLYKYR 60
************************************************************
TM1 (66-89)            A-Loop __ TM2(104-127)  
AG83-S          WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
2001-S          WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
MC7-S           WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
MC4-R           WWLREYVAEFFGTFFLVTFGTGVIATTVSHAGNAASYQSNSSYMAITLGWGFGLTIGLFL 120
MC8-R           WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
MC9-R           WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
RK1-S           WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
MS2-S           WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
NR3A-R          WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
RMP142-R        WWLREYVAEFFGTFFLVTFGTGVIATTVFHAGNAASYQSNSSYMAITFGWGFGLTIGLFL 120
**************************** ******************:************
           B-Loop         TM3 (140-163)         C-Loop
AG83-S          SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
2001-S          SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
MC7-S           SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYRLFKSHFDDAQKA 180
MC4-R           SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
MC8-R           SMAVSGGHLNPAVTLANCVFGAFPWIKLPGFSLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
MC9-R           SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
RK1-S           SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
MS2-S           SMAVSGGHLNPAVALANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
NR3A-R          SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
RMP142-R        SMAVSGGHLNPAVTLANCVFGAFPWIKLPGYFLAQFLGGLVGAANTYGLFKSHFDDAQKA 180
*************:****************: *************** ************
TM4 (201-224)     D-Loop
AG83-S          LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
2001-S          LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
MC7-S  LLPNETMPSKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
MC4-R           LLPNETMAPKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
MC8-R           LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
MC9-R           LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
RK1-S           LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
MS2-S           LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
NR3A-R          LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
RMP142-R        LLPNETMASKYSGIFATYPNVANTYAVWSEVFNTMALMMGILAITDPRMTPAVNYKPVAI 240
*******..***************************************************
TM5 (237-256) E-Loop TM6 (287-310) 
AG83-S          GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
2001-S          GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
MC7-S           GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
MC4-R           GLLLFVIGITSGINSSYGPNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
MC8-R           GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
MC9-R           GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
RK1-S           GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
MS2-S           GLLLFVIGITSGINSSYGLNPERDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
NR3A-R          GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
RMP142-R  GLLLFVIGITSGINSSYGLNPARDLSPRILSAMLWGSEPFTLYSYYFWIPLVAPFVGALL 300
**********:******* ** ************************************** 
AG83-S          GMFLYVFFIIPPNF 314
2001-S          GMFLYVFFIIPPNF 314
MC7-S           GMFLYVFFIIPPNF 314
MC4-R           GMFLYAFFIIPPNF 314
MC8-R           GMFLYVFFIIPPNF 314
MC9-R           GMFLYVFFIIPPNF 314
RK1-S           GMFLYVFFIIPPNF 314
MS2-S           GMFLYVFFIIPPNF 314
NR3A-R          GMFLYVFFIIPPNF 314
RMP142-R        GMFLYVFFIIPPNF 314
*****.********
Figure 4. AQP1 protein sequences from the SAG-S and the SAG-R L. donovani (VL and PKDL) isolates were aligned using the CLUSTAL 2.0.11 multiple
sequence alignment program. Transmembrane topology of the proteins was predicted using an online transmembrane topology prediction server
(HMMTOP; www.enzim.hu/hmmtop). Six transmembrane domains (TM1–TM6) and five helical loops (A–E) connecting transmembrane domains
were identified. Loops B and E containing conserved Asn-Pro-Ala (NPA) motifs form short a-helices that fold back into the membrane from the
opposite side, forming a channel for glycerol transport. Two NPA motifs are boxed. Point mutations are marked in red, and Glu185 and Arg263
(corresponding to Glu152 and Arg230 in the partial sequence14) amino acid residues linked to SbIII susceptibility are shown in blue. This figure
appears in colour in the online version of JAC and in black and white in the print version of JAC.
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Promastigotes of AG83-S, an antimony-susceptible isolate over-
expressing AQP1, became 3.1-fold more susceptible to SbIII
when compared with the promastigotes of the parent strain
(transfected with the control vector), the IC50 values being
25+2.5 and 8+3 mM, respectively (Figure 6b). MC4-R promasti-
gotes overexpressing AQP1 were 4.2-fold more susceptible to
SAG when compared with the IC50 of promastigotes of the
parent strain (transfected with the control vector), the IC50
values being 68+4.0 and 16+2.7 mM, respectively. Increased
uptake of SbIII by the resistant isolate MC4-R is possibly respons-
ible for the re-sensitization of this drug-resistant mutant.
Discussion
The mechanism of antimony resistance in Leishmania has been
studied extensively. An increase in resistance to SAG has led to an
upsurge in therapeutic failure. In the absence of limited
chemotherapeutic alternatives, it is necessary to identify bio-
markers for antimony resistance to improve the chemotherapeutic
approach in field conditions. It has been reported previously that
the trivalent form of the antimonial drug, SbIII, is the prodrug
that is formed by conversion of pentavalent antimony (SbV) by a
putative metalloid reductase present in the macrophages.28
Resistance to antimony in both the laboratory-raised resistant
strains and clinical isolates has been associated with: (i) over-
expression of the enzymes of the thiol biosynthetic pathway;29,30
(ii) increased expression of the ABC transporter, MRPA, which
sequesters the SbIII–thiol conjugate;7,31 and (iii) decreased
uptake of the drug by low expression of the AQP1 gene,11,13,23
which codes for the protein responsible for the uptake of SbIII.
Disruption of one of the alleles of the AQP1 gene in L. major has
been reported to result in a 10-fold increase in resistance to
SbIII.11 However, increased expression of AQP1 in an
antimony-resistant parasite resulted in reversal of resistance in
L. major.11,13 Gene expression analysis of natural SbV resistance
in L. donovani isolates from Nepal showed that down-regulation
of AQP1 led to reduced uptake of antimonite.22 Our previous
studies on a small subset of Indian clinical isolates, however, indi-
cated that while down-regulation ofAQP1was one of the mechan-
isms of antimony resistance, it was not a universal feature in all the
isolates.23 Furthermore, recent reports have shown that a single
mutation at Glu152 (to alanine) in the extracellular C-loop of
LmAQP1 abrogated metalloid permeability, showing that Glu152
is critical for metalloid transport.14
In the present study, we have used both VL and PKDL isolates
that were either susceptible or resistant to SAG. Although there
(b)
(a)
A
2 5
461 3 A
N
P
A
NP
E
C
B COOH
Cytosol
Extracellular
MC7-S: G168R
A188P
H2N
*
*
* D
Figure 5. (a) An hourglass model of aquaporin according to Jung et al.26 and Zardoya et al.,27 showing mutations in L. donovani. Mutations found in
the strain MC7-S are shown in the box. (b) Conserved signatures of the AQP1 protein of MC4-R, MS2-S and MC8-R that were deduced from the
comparative analysis of the multiple alignment in Figure 4. Asn-Pro-Ala (NPA) motifs are marked in red and amino acid mutations are marked in
blue. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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are several biological studies that have been performed on VL
strains of Leishmania, studies on PKDL strains are few, primarily
because of the difficulty in culture isolation of the parasite
from dermal lesions. Molecular genotyping of VL and PKDL iso-
lates by PFGE and PCR-RFLP of the ITS region of L. donovani clini-
cal isolates showed polymorphism in the isolates. Genetic
heterogeneity between the VL and PKDL isolates observed
in the present study and also among the VL isolates from
the same geographic region is in agreement with previous
studies.15,32 However, it would be interesting to monitor the
parasite population with other powerful genotyping tools in
order to establish the differences between PKDL and VL isolates.
The in vitro susceptibility profiles obtained with SbIII corre-
lated well with the clinical information, and accordingly the iso-
lates were classified as SAG-S or SAG-R. Out of eight PKDL
isolates used in the present study, six were found to be refractory
to antimony. In India, PKDL, a complication of VL, occurs as a
sequel to kala-azar after 2–7 years of treatment.33,34 The high
incidence of refractoriness to SAG in these PKDL isolates may
be because of the previous exposure of the parasites to SAG
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Figure 6. (a) Accumulation of SbIII in AQP1-overexpressing L. donovani field isolates as measured by ICP-MS. Promastigotes were incubated with
100 mM SbIII for 30 min at 278C as described in the Materials and methods section. Data are shown as means+SD of two replicate experiments
with triplicates in each set. *P,0.01 compared with respective controls. Northern blot analysis (insets) of vector-transfected controls and
AQP1-transfected lines was performed as described in the Materials and methods section. (b) Effect of different concentrations of SbIII on
SAG-susceptible isolate AG83-S and SAG-resistant field isolate MC4-R promastigotes, transfected with vector alone or pspaneoa-AQP1. Each data
point represents the mean+SD of three determinations.
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during treatment for VL. Alternatively, the higher doses of SAG
that are required for treatment of PKDL may be necessitated
by host factors. Recent clinical and experimental data show
that SAG has a profound influence on the immune response.35
Saha et al.35 have recently reported that SAG had a varying
effect on the production of interleukin (IL)-10 and transforming
growth factor (TGF)-b levels in PKDL and VL patients. It is there-
fore possible that these factors may also be responsible for sus-
ceptibility/resistance to antimony. However, further studies are
required to verify this hypothesis.
We checked the differences in SbIII accumulation in the
antimony-susceptible and -resistant clinical isolates and its cor-
relation with the SAG susceptibility profile. We found 2- to
7-fold reduced accumulation of SbIII in the SAG-resistant field
isolates when compared with the susceptible isolates.
We further characterized the role of AQP1 in SbIII transport in
the Indian clinical isolates. Southern blot hybridization showed
polymorphism in the AQP1 gene in both VL and PKDL isolates.
While most strains had one copy of the AQP1 gene, RK1-S, an SAG-
susceptible isolate, had two copies of the AQP1 gene. To our sur-
prise, amplification of theAQP1 gene was observed in the resistant
strain NR3A-R. Interestingly, molecular karyotyping of NR3A-R
showed variation in the genotype compared with other PKDL
and VL isolates. No polymorphism was observed in the AQP1
gene in the VL isolates even though genetic heterogeneity was
observed among the VL isolates MC7-S, MC4-R, MC8-R and MC9-R.
Down-regulation of AQP1 RNA expression as determined by
real-time PCR was observed in the seven resistant isolates. Two iso-
lates, NR3A-R and MC8-R, however, showed up-regulation of AQP1
RNA. In the SAG-R strain NR3A-R, increased AQP1 RNA expression
correlated with the amplification to the AQP1 gene. In another
resistant strain, MC8-R, although up-regulation of RNA levels
similar to that of NR3A-R was detected, gene amplification of the
AQP1 gene was not present. An SAG-susceptible isolate, RK1-S,
having two copies of the AQP1 gene, was found to have an RNA
expression level similar to that of the other susceptible isolates
having a single copy of the AQP1 gene. We have reported similar
exceptions in AQP1 expression in clinical isolates previously.23
Since we observed this discrepancy in some of the isolates and
were unable to correlate the down-regulation of AQP1 expression
to SAG resistance, we decided to check if a single mutation at
Glu152 (corresponding to Glu185 in the full-length sequence) to
alanine in the extracellular C-loop of AQP1 abrogated metalloid
permeability. This mutation has been reported to be critical for
metalloid transport.14 In order to do so we decided to clone and
sequence the AQP1 gene of these isolates. Although we found
differences in the AQP1 sequences of strains MC7-S, MC4-R,
MC8-R and MS2-S, the observed changes were not at positions
Glu152 and Arg230 which previously have been shown by site-
directed mutagenesis to be responsible for metal (AsIII/SbIII)
transport.14,36 It will be interesting to see if one or all these altera-
tions in the AQP1 gene have a role in metalloid transport.
Analysis of L. major and Leishmania infantum genomes shows
the presence of five AQPs: AQP1; AQPa; AQPb; AQPg; and AQPd.36
While the role of L. major AQP1 has been established in detail,
the role of other AQPs has not yet been worked out. It is possible
that one of these AQPs may also have a role in metalloid trans-
port. However, this needs to be established.
Previous findings elucidated that resistance in laboratory
strains is also operational in field isolates as the overexpression
of AQP1 conferred susceptibility to the resistant isolates.13 It
has been reported previously that transfection of LmAQP1 in a
pentostam-resistant field isolate sensitized the parasite in the
macrophage-associated amastigote form.11 In the present
study, we also found that transfection of AQP1 in an
antimony-resistant field isolate conferred increased expression
and susceptibility to antimony, and facilitated SbIII uptake.
Drug resistance could be due to decreased influx and/or
increased efflux of the drug. In Leishmania, AQP1 has been
shown to mediate the uptake of SbIII.11 Down-regulation of
AQP1 in antimony-resistant clinical isolates from Nepal and
India has been reported previously.22,23 The role of the ABC trans-
porter, MRPA, in conferring antimony resistance by sequestration
of metal–thiol conjugates in Leishmania clinical isolates has also
been reported previously.7 MRPA has been reported to decrease
influx of antimony rather than increase efflux.37 A metal efflux
pump has also been reported in the Leishmania plasma mem-
brane. Like MRPA, this efflux pump also recognizes the metal
conjugated to thiols,10 and requires ATP. The identity of this
efflux pump is not known. Previous reports have shown no signifi-
cant role for this efflux system in antimony resistance.38 Further-
more, an increased level of trypanothione (TSH), the main
cellular thiol in Leishmania, has been observed in mutants
selected for antimony resistance.10
All the resistant clinical isolates used in the present study
showed increased expression of MRPA, altered thiol levels
(S. Mandal, M. Maharjan and R. Madhubala, unpublished
results) and decreased uptake of SbIII. However, down-
regulation of AQP1 was not observed in all the resistant clinical
isolates in the present study. As clearly seen from our present
and previous studies, resistance mechanisms found in laboratory
strains can be found in clinical isolates, but there are exceptions.
This would indicate that reduced accumulation observed in these
cells results from a channel or transporter different from AQP1 or
from a more active efflux system.38
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